Trials / Completed
CompletedNCT00804934
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Retina Institute of Hawaii · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.
Detailed description
To determine mean change in visual acuity at 6 and 12 months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lucentis | 0.5mg Lucentis every four months |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-02-01
- Completion
- 2009-01-01
- First posted
- 2008-12-09
- Last updated
- 2012-05-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00804934. Inclusion in this directory is not an endorsement.